Biotech Embrace IT Knowledge

— We have succeeded in bringing more IT knowledge to the Biotech world, says Project Manager of PERMIDES D.B.R.K. Gupta Udatha.

 

Merging IT and Biotech
Together with five European clusters, Oslo Cancer Cluster have been managing a Horizon 2020 EU project “PERMIDES”. The cluster-to-cluster projects main goal was to stimulate collaboration between biotech companies and IT companies, in the end to create more innovative and personalized cancer treatments.

The total volume of what the project has managed to achieve makes it a success, Gupta Udatha believes.

— The IT sector is developing fast. We now have tools like Big Data, Machine Learning, Blockchain and more. All this can be amazingly helpful for a Biotech company if they get help understanding the technology. This is what PERMIDES has provided! On a more basic level we have freed Bio-businesses from the clutching grasp of excel sheets and presented more effective computer solutions.

Results and Speed
And the program has provided an abundance of results.

  • PERMIDES supported 88 Small and medium-sized enterprises (SMEs) of the bio-pharmaceutical sector from 18 European countries
  • 119 grant applications have been submitted for innovation projects
  • 51 are funded for a total of € 2.65 M.

Furthermore, biopharma SMEs in need of consultancy services could apply for consultancy vouchers, each amounting to a maximum of 5,000 Euros. From a total of 91 applications, 41 are now financially supported by consultancy vouchers with a total funding volume of 261,000 Euros.

Another successful part of PERMIDES is how effective it has been

— Speed is a key factor of PERMIDES, which funds innovation projects for a maximum of half a year. The success of PERMIDES is further supported by the comparatively short review process of a maximum of three months between application submission and funding commitment, says Gupta Udatha.

Full Overview
If you want to take a closer look at what the PERMIDES project has achieved, check their brand new database.

— There you will not only find extensive information about the projects, but also about the project partners. Take a look at this information source and see for yourself the innovative solutions of European SMEs. Currently the projects of the first cut-off date are available. In the next few weeks, we will also add the projects of the second cut-off date and publish the Consultancy Voucher projects, says Gupta Udatha.

PERMIDES database.

For funded bio-pharmaceutical companies, there is still the possibility until mid of 2018 to receive a follow-up coaching by the PERMIDES team. The coaching includes, for example, information about further funding opportunities, support in applying for additional funding or further networking with companies and research institutions from the IT industry.

Welcome to Our New Members

Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members.

 

The Importance of Getting There
Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and pharmaceuticals shipments.  Simply put, their expertise is getting things where they are supposed to go – safely and in compliance. They are one of the leading logistics providers in the world, with over 74 000 employees and 1 300 offices spread all over the globe.

For Oslo Cancer Cluster members, Kuehne+Nagel’s a special competence can be applied to help us reach our shared goal of accelerating the development of innovative cancer treatments.  They are CEIV-certified (IATA airfreight pharmaceutical), and WHO GDP (good distribution practices) compliant for pharmaceutical products and specialized in the distribution of pharmaceutical and healthcare shipments. For example, biotechs can have very specific requirements when it comes to transport of products. In many instances, it is crucial to transport biological tissue at a certain temperature under certain conditions.

Protecting and Developing Innovation
Another company rich in tradition is the Norwegian firm Bryn Aarflot. They are a full-service Intellectual Property (IP) firm with a total of 45 people located in central Oslo. Their diverse IP practice areas include strategic counselling, intellectual property creation, capture and clearance through to protection, commercialization, enforcement and maintenance, contract drafting and negotiations, as well as IP litigation.

Their approach is to get to know the client’s business and understand their technology, products and goals, and counsel them on how to utilize the intellectual property to generate revenue and increase market power. This is a positive addition to the Cancer Cluster community, where biotechs innovate on the basis of their own intellectual property.

Helping Start-Ups
Cellmover is truly a company that goes to the core of what we do here at Oslo Cancer Cluster. It’s a Biotech start-up, led by Oslo University Hospital cancer specialist Marit Inngjerdingen.  Cellmover’s goal is to develop immunotherapeutic products directed at the treatment of cancer. They specifically design products to enhance survival, activity, and targeting of immune cells used for cell therapy.

As a Oslo Cancer Cluster member, Cell Mover can benefit from all the help our cluster can provide. In the cluster environment, it is easier to meet and learn from companies with similar technologies, or it could prompt creative ideas from companies working with something quite different.  The benefits from learning the necessary “know-hows” to turn a start-up into a successful business and develop cancer treatment.

Do You Need Help Recruiting?
If you work with cancer research, there is one thing you certainly need and that is competent people. Mercuri Urval exists to secure that organizations always have the right people in place to produce the best possible result. They are a leading – Stockholm based – global Executive Search, Professional Recruitment and Talent Advisory firm. One of their fields of expertise is recruitment within the Life Sciences. For more than 50 years Mercuri Urval has recruited human resources for the healthcare industry.

 

 

 

 

 

10th Cancer Crosslinks: Precision Treatment Reviewed

For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data.

 

Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a closer look at developments over the last decade, and highlighted “Precision Treatment: Exploiting Recent Advances – Fast and Furious?”.

Weber Gazed into the Crystal Ball
The leading immunotherapy expert professor Jeffrey S. Weber visited Cancer Crosslinks for a second time. Weber has worked with immunotherapy for 30 years.  He provided an overview on recent advances. He shared new data showing that the combination of a certain vaccine and a type of immunotherapy called Checkpoint inhibitors, are especially effective against cancer. He also gazed into the crystal ball and made predictions on the future of cancer treatment. Weber is optimistic and thinks there are several promising combinations of precision treatments on the horizon.  He believes we can hope for a survival rate of 70-80 percent for people with certain cancers.

A Fiber Diet is Recommendable
Professor Laure Bindels from Belgium explored the theme of Microbiome, Cancer and Cachexia. Diet can be an important tool to fight cancer and cancer symptoms. Her research on mice indicates that changing to a fiber-rich diet can prevent undernourishment and increase the survival rate for cancer patients.

Hege Russnes and Anne Hansen Ree introduced us to the MetAction project where they conduct extended personal diagnostic testing to give cancer patients better and more effective treatment.

From the USA, we were introduced to precision treatment of gynecological cancer from Douglas A. Levine.  He was followed by Professor Andreas Engert, who raised the hot topic of establishing joint European guidelines for treatment across Europe for hematological cancer.

A Big Maybe to Big Data
The last speakers of the day where Assistant Professor Marcela Maus from Harvard Medical School, and Elisabeth Wik and Marc Vaudel from the University of Bergen. Professor Maus explained the use of CAR T- cells in cancer treatment. CAR-T Cells are T-cells with modified receptors to make them more effective against certain diseases, in this case cancer.

Elisabeth Wik and Marc Vaudel, with backgrounds from cancer research and computer science, discussed the use of big data in cancer research and treatment. Will big data revolutionize cancer treatment? The answer is maybe. We don’t know yet, it has potential.  We need to continue exploration, research, and collaboration to find out.

Download the Presentations
For those of you who missed the event or would like to revisit:

You may watch most of the presentations here.

You can download presentations from the meeting here:

Opening and Welcome with Jutta Heix from Oslo Cancer Cluster and Anne Kjersti Fahlvik, Executive Director Innovation, The Norwegian Research Council.

Jeffrey S. Weber. Opening Keynote: Cancer Immunotherapy – The Journey So Far and Where We Are Heading.
Jeffrey S. Weber, Professor, Deputy Director and Co-Director, Melanoma Program, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, USA.

Laure Bindels. International Keynote: The Microbiome, Cancer and Cachexia.
Laure Bindels, Louvain Drug Research Institute, Université catholique de Louvain, Belgium.

Hege G. Russnes and Anne Hansen ReeFrom Feasibility to Utility in Precision Medicine – Experiences from the first Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer.
Hege G. Russnes, Senior Consultant and Researcher, Oslo University Hospital, Norwegian Radium Hospital, Norway
Anne Hansen Ree, Professor, Akershus University Hospital, University of Oslo, Norway

Douglas A. Levine. International Keynote: Precision Medicine for Gynecologic Cancers – Opportunities and Obstacles.
Douglas A. Levine, Professor, Director of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center & Head, Gynecology Research Laboratory, NYU Langone Medical Center, New York, USA.

Andreas Engert. International Keynote: Roadmap for European Hematology Research and Hodgkin Lymphoma: (Immuno)therapy, Late Effects and the Way Forward.
Andreas Engert, Professor for Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Germany.

Marcela V. Maus. International Keynote: The Next Generation of Engineered T-cells for Immunotherapy of Hematological and Solid Tumors.
Marcela V. Maus, Assistant Professor, Harvard Medical School & Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, USA.

Marc Vaudel  and Elisabeth Wik: Making Sense of Big Data for Oncology Patients – Vision and Reality
Marc Vaudel, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital and KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
Elisabeth Wik, Centre for Cancer Biomarkers, University of Bergen and Department of Pathology, Haukeland University Hospital, Norway

Follow the 10th Cancer Crosslinks: Stream and Program

Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research.

 

This year’s conference will focus on Precision Treatment in cancer research with the headline: Exploiting Recent Advances – Fast and Furious?

Check out the program here.

Follow the stream
Registration for the event is now closed, but the whole event will be streamed and broadcasted here at the website. Just follow this link and you can follow the event live:

Follow the stream here.

Curida Takover Secures Norwegian Production

To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS.

 

Continued Production at Ås
Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators.

«Ås produksjonslab» is a company rich in tradition, it has nine employees and produces many products for Norwegian pharmacies, while also facilitating production on an assignment order basis.

Curida purchase Ås produksjonslab from The Norwegian Apothecary Society (Apotkerforeningen), a union of Norway’s 900 Pharmacies.

However, the lab will continue their production at Ås also after the takeover. And, with a yearly revenue of 21 million NOK, Leif Rune Skymoen, CEO at Curida, believes the takeover combined with the general growth of the company will help balance the budget the upcoming year.

— We are making these strategic moves because Curida gathered 50 million NOK in December by releasing an equal amount of stocks to Canica and Klavness Marine. Furthermore, Investinor was given an option on 25 million NOK worth of stocks, says Head of the Board of Directors, Per S. Thoresen at Curida. Investinor will decide at the end of January.

Securing Norwegian Expertise
As early as December Thoresen informed that part of the money gathered in the end of the year emissions would be used to buy production facilities.

And CEO Per T. Lund at The Norwegian Apothecary Society is also happy with the takeover. He says in a press release that this will contribute to a strong base of Norwegian pharmaceutical production. Additionally, it secures Norwegian Pharmacies delivery of pharmaceuticals in strong demand.

— We are strengthening Norwegian pharmaceutical production and securing important expertise, Thoresen explaines.

Curida is not only securing Norwegian production, they have also become important for Norwegian war time infrastructure. Late 2017 Curida signed a letter of intent with the Norwegian Armed Forces. They now supply raw materials and are responsible for pharmaceutical manufacturing in situations of emergency preparedness, which means in case of conflict, state of war or general emergency.

Fremtidens kreftbehandling – ta med egne data!

Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg.

Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor.

Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse.

Et nytt sykehus må bygges slik at data enkelt kan samles inn og hjelpe pasientene.

La også appene fortelle
Hva er så helsedata? Se for deg en lege med stetoskop rundt halsen. Leger har i «alle år» brukt stetoskopet til å registrere informasjon fra kroppens indre; høre om hjerterytmen er normal eller om lungene surkler. Stetoskopet samler helsedata og hjelper frem riktig diagnose ved å innhente skjult informasjon.

I dag har vi heldigvis enda flere hjelpemidler til å samle inn helsedata.

Og Helse-Norge samler inn data som aldri før. Informasjon kan komme fra analyse av blod og spyttprøver eller undersøkelser som EKG, MR og CT. Forkortelsene er mange, instrumentene enda flere.

Prøver, testing og overvåking gjennomføres i økende grad av digitale verktøy. Dette gir behov for nye effektive møteplasser. Digitale møteplasser der flere typer kreftleger kan møtes for å diskutere behandlingen av en pasient uten å møte opp fysisk. Digital infrastruktur vil kunne effektivisere og forbedre hverdagen til våre kreftspesialister betydelig.

Det pasienten selv forteller, er mange ganger også uvurderlig for å fastslå diagnose og behandling. I dag registreres presis informasjon om vår hverdag på ulike private apper via mobiltelefoner. Helsepersonell får dermed vite mye mer om pasienten og kan legge til rette for bedre pasientoppfølging og behandling.

Data-arkitektur
Hvordan helsedata samles inn og tas i bruk må endres!

Det tas millioner av blodprøver på et sykehus, og god sykehusarkitektur kan bidra til bedre innsamling av blodprøver og biologisk materiale. Mange tradisjonelle sykehusprosesser er allerede automatisert, og sykehusarkitekter må ta hensyn til hvordan slik ny teknologi endrer arbeidsflyt og behov.

Vi har allerede nødvendig teknologi for digital rapportering, vi må bare ta den i bruk

Og videre, hvordan skal dataene kategoriseres og lagres? I dag registreres ofte samme data manuelt av lege og sykepleier flere ganger. Dette er frustrerende for pasienter og helsepersonell, i tillegg til at det kan være utfordrende for konfidensialitet, kvalitet og tilgjengelighet.

Slik trenger det ikke være. Vi har allerede nødvendig teknologi for digital rapportering, vi må bare ta den i bruk. Helsedata vil også hjelpe sykehuslogistikken. Innfører vi elektronisk sporing av pasienter, kan vi se hvor pasienter, utstyr og personell er til enhver tid. Det vil forenkle behandlingsplanlegging og forhindre mye unødig løping i gangene.

Ikke skuff statsministeren!
Sykehus i Norge fungerer godt, men den nye klinikken må ta helsedatarevolusjonen på alvor. Det lar seg gjøre. Og Erna Solberg er enig. På IBM-konferansen i november sa hun: «Pasientdata skal gå fra lagrede data til aktivt å benyttes som beslutningsstøtte.» Til alle beslutningstagere: Ikke skuff statsministeren! Bygg et bygg som utnytter helsedata best mulig. Pasientene vil takke dere.

Her finner du artikkelen på Aftenposten sine egne sider.

Breakthrough Agreement for Phoenix Solutions

A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions.

Early Christmas Present
As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing for ACT, short for Acoustic Cluster Therapy, a technology platform for targeted drug delivery. CEO at Phoenix Solutions, Per Sontum, emphasized the importance of gaining a manufacturer that had experience with similar products.

“We are excited to sign this agreement and get GE on board as contract manufacturer of our product. With more than 20 years of experience producing Sonazoid and Optison, GE`s Oslo organization is the world leading site for the manufacturing of this class of pharmaceuticals.”

From GE`s Womb
The collaboration, however, is not totally out of the blue. Phoenix Solutions sprung out from GE Healthcare in 2013. GE`s General Manager for Norway, Bjørn Fuglaas believes this tie between the two companies is an advantage:

“We are very pleased that Phoenix has chosen to work with GE for this project, which is in line with the expectations we had when the company was spun out of GE in 2013. This is an area of interest and we believe GE to be uniquely positioned in this field given existing and strong capabilities within production of disperse pharmaceuticals, and microbubbles in particular”, he says.

This agreement also secures what is called Good manufacturing practice (GMP) for Phoenix Solutions. Making their product and company a safer potential for investors and further along in their development than time should suggest.

A Very Promising ACT
ACT is a special and interesting targeting device. It is an ultrasound mediated drug delivery system that specializes in beating the vascular barrier. It has a wide range of therapeutically useful applications, but Its primary use being the ability to deliver sufficiently high concentrations of drug to the tumor without contaminating its surroundings. Phoenix thinks ACT is a promising targeting system for pancreatic, liver, triple negative breast and prostate cancers, and has extremely promising pre-clinical results so far.

Oncoinvent With New Lab and Bright Future

The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin.

A Good Year
2017 has been a good year for Oncoinvent. The company has now relocated and built new office and laboratory facilities, grown from four to twelve employees, and raised new capital. CEO at Oncoinvent Jan A. Alfheim believes that this represents a significant milestone for the company and will enable the company to further develop Radspherin®, a novel alpha-emitting radioactive microparticle designed for treatment of metastatic cancers in body cavities.

And Oncoinvent ends the year in fashion by opening brand new laboratory and research facilities. A lot of interested people came to tour the new facilities, observing an impressive lab with special infrastructure. Treating radioactivity, and circulating air in a facility that treats radioactive materials, calls for an extra advanced ventilation system.

Lab With all the Facilities
The idea of the new research facility is to be able to contain the whole production line, from research to drug manufacturing, to one location. All this contained in an area of 581 m2.

Creating a modern lab with the capabilities to treat radioactive materials in an active and well populated part of Oslo demands very strict guidelines. The production suites in the facility are constructed to be qualified for Good Manufacturing Practice (GMP) for production of Medical Product Candidates. Systems for purifying and monitoring of air and water quality as well as the removal of any potential radioactivity have been installed to ensure the safety of the operators, population and the environment.

The Production and Research areas of the laboratory will facilitate both the development of the Radspherin program and other discovery projects of the Company.

A Weapon for Precision Medicine
Radspherin® has been shown to cause a significant reduction in tumor cell growth an it is anticipated that the product can potentially treat several forms of metastatic cancer. Oncoinvent is developing Radspherin® as a ready-to-use injectable product that seeks out cancer tumors and destroys them from inside by emitting its radioactive content.

The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis, a rare type of cancer that occurs in the peritoneum, the thin layer of tissue that covers abdominal organs and surrounds the abdominal cavity. Additionally, Oncoinvent has lined up a collaboration with European and American clinical research centers for the clinical development Radspherin®.

Four Cluster Companies Get Innovation Reward

Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations!

Important with early financing
Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. Therefore, Innovation Norway has given Oslo Cancer Cluster 1000 000 NOK to reward excellent innovation and collaboration activity at an early stage. A cluster is all about reaping the benefits of collaboration and Oslo Cancer Cluster has awarded the Innovasjonsrammen-money to four of their promising member companies. Hopefully this will inspire other potential financers to support Norwegian bio businesses at an early stage.

Prize money awarded
NorGenoTech AS     150 000 NOK
Clever Health           100 000 NOK
Phoenix Solutions    500 000 NOK
Nacamed                 150 000 NOK

Hanne Mette Kristiansen from Innovation Norway and Ketil Widerberg from Oslo Cancer Cluster, as well as Bjørn Klem form Oslo Cancer Cluster Incubator, handed out checks for Innovasjonsrammen. Her received by Sergey Shaposhnikov from NorGenoTech, Jon-Bendik Thue from Clever Health, Per Christian Sontum from Phoenix Solutions and Christina Westerveld Haug and Lars Gunnar Fledsberg from Nacamed.

Bringing Together Tech Knowledge
At the 5th floor of Oslo Cancer Cluster the four companies each received their innovation award handed out by Hanne Mette Kristiansen from Innovation Norway, Ketil Widerberg from Oslo Cancer Cluster and Bjørn Klem from Oslo cancer Cluster Incubator.

Ketil Widerberg, General Manager at Oslo Cancer Cluster, thanked Innovation Norway for providing the money and the panel of experts that helped pick the four deserved winners. – This money helps to remove some risk from the early stages of the innovation process, said Widerberg.

Bjørn Klem from Oslo Cancer Cluster Incubator added that it had been a very difficult process choosing the winners from the eight companies that applied. However, giving out prize money requires hard choices and he applauded the versatility at display.

–I think it is interesting that the four companies represent four different approaches within cancer research. Four different technologies. And getting them together here today is what Oslo Cancer Cluster and the incubator is all about: Getting different people together sharing knowledge and impulses!

Hanne Mette Kristiansen from Innovation Norway explained that Innovasjonsrammen was a way of reaching out to companies that usually avoided their attention. Startups that had not yet attracted any serious business attention, but nevertheless had very promising projects.

About the companies
Sergey Shaposhnikov from NorGenoTech explained that the money was coming in very handy. They are a company, as he explained it, straight out of the lab. Now they could start turning their research into business.

Clever Health has a more customer or patient oriented focus in their business model. Jon-Bendik Thue from Clever Health explained how a widespread disease as prostate cancer needs a way of differentiating between the patients that need treatment and the ones that do not.

Per Christian Sontum from Phoenix Solutions was very thankful for the award and money. He showed everybody how ultrasound can be way of targeting cancer cells with precision drug delivery.

And the event was elegantly rounded off by Christina Westerveld Haug and Lars Gunnar Fledsberg from Nacamed. Nacamed’s business goal is to produce nanoparticles of silicon material for targeted drug delivery of chemotherapy, radiation therapy and diagnostics to kill cancer cells. She explained that the money would be put in use straight away. Preparing for important trials after Christmas.

Giving Tuesday Crowdfunds for Cancer

You have probably heard of Black Friday. Now introducing Giving Tuesday: A day all about giving rather than buying. Eight Norwegian YouTubers have chosen to crowdfund on behalf of The Norwegian Cancer Society as part of Giving Tuesday. Raising money for cancer research and cancer patient care. A week before the big day five of them visited Oslo Cancer Cluster.

 

Tuesday the 28th of November, conveniently a couple of days after the shopping bonanza of Black Friday, is Giving Tuesday. It’s an international event. Started in 2012 by the 92nd Street Y and the United Nations Foundation as a response to Black Friday and commercialization and consumerism in the post-Thanksgiving season.

Live Social Media Broadcast
On the day the Norwegian youTubers are staging a broadcast marathon on social media. At DnB Headquarters (Bjørvika) they all come together for a live broadcast so everybody can follow the crowdfunding and view their videos during Giving Tuesday.  And there are a lot of them. 10 other charities are being crowdfunded on the day with youTubers raising money on their behalf.

Learn more about what’s happening here.

Learning About Cancer Research
The last couple of weeks the youtubers funding for The Norwegian Cancer Society have learned about cancer research and the fight against cancer. They have visited the Society’s new Science Center learning about the history of the disease and afterwards they spent a day getting updated on current cancer research at Oslo Cancer Cluster.

At Ullern Innovation Park, the home of Oslo Cancer Cluster, they got to see researchers in action and learned about the recent advances in cancer research. How researchers now are trying to trigger the immune system in the fight against cancer and how we are getting better at producing medicines that target cancer tumors directly. They also got see how research and innovation merges together with education at the Innovation Park. Here researchers, Bio Businesses and Ullern Upper Secondary School share the same building and cooperate.  Learn more about this unique cooperation.

With this new knowledge on cancer they are well prepared to crowdfund a lot of money for The Norwegian Cancer Society and cancer research!

About the YouTubers
Christoffer Ødegård (17) Specializes in FIFA. Playing live games on youTube.

Emil Saglien (15) Also into football. Actually, about his life, but his life seems to be football.

Sara Høydahl (19) Vlogs about many things, but has had special success with a Friday special on murder mysteries!

Truls Valsgård (23), Truls is a full time youtuber. Produces videos daily about his own life.

Tuva Robsrud (16) From Bærum and vlogs about fashion and make up.